Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Core Viewpoint - Halozyme Therapeutics, Inc. has announced the pricing of $650 million in 0% convertible senior notes due 2031 and $650 million in 0.875% convertible senior notes due 2032, with an option for initial purchasers to buy an additional $100 million of each series [1][4]. Summary by Sections Convertible Notes Details - The 2031 Notes are senior, unsecured obligations with no regular interest and no principal accretion, while the 2032 Notes will accrue interest at an annual rate of 0.875% payable semi-annually [2]. - The initial conversion rate for both series is 11.4683 shares per $1,000 principal amount, equating to a conversion price of approximately $87.20 per share, representing a 27.5% premium over the closing price of $68.39 on November 6, 2025 [2]. Use of Proceeds - The company expects to receive net proceeds of approximately $1.274 billion, or $1.47 billion if the option for additional notes is fully exercised, after deducting discounts and expenses [4]. - Approximately $182.7 million of the proceeds will fund capped call transactions, while about $1.020 billion will be used to repurchase existing convertible notes due 2027 and 2028 [4][5]. Capped Call Transactions - Capped call transactions have been established to cover the shares underlying the convertible notes, with a cap price of $136.78 per share, representing a 100% premium over the last reported sale price [3][7]. - These transactions are expected to reduce potential dilution upon conversion of the notes and offset cash payments if the market price exceeds the cap price [7]. Market Impact - The note repurchases may influence the market price of the company's common stock and convertible notes, potentially affecting the conversion price and the number of shares received upon conversion [6][10]. - The company anticipates that hedging activities related to the capped call transactions could also impact the market price of its common stock [8][9]. Company Overview - Halozyme is a biopharmaceutical company focused on innovative drug delivery solutions, particularly through its ENHANZE® technology, which facilitates subcutaneous delivery of drugs [14][15]. - The company has partnered with major pharmaceutical firms and has a presence in over 100 global markets, impacting approximately one million patients [14].